Michelle M. Hanna, Ph.D. – CEO and Scientific Director
Dr. Hanna, the founder and CEO of Ribomed Biotechnologies, received her Ph.D. in Chemistry from the University of California, Davis and did her postdoctoral work in Biochemistry and Molecular Genetics as an American Cancer Society Postdoctoral Fellow at the University of California, Berkeley. She was an Assistant Professor of Biological Chemistry at UC Irvine College of Medicine where she received Young Investigator awards from the American Cancer Society and the Beckman Foundation. Dr. Hanna was a tenured Associate Professor of Chemistry and Biochemistry at the University of Oklahoma until she founded Ribomed Biotechnologies. Dr. Hanna has been awarded over $10 million in grants and contracts from the American Cancer Society, the National Cancer Institute (NCI)/National Institutes of Health (NIH), the National Science Foundation (NSF), the National Institute of Allergies and Infectious Diseases (NIAID)/NIH, the Defense Advanced Research Projects Agency (DARPA), and the Homeland Security Advanced Projects Agency (HSARPA). Her work has resulted in numerous peer-reviewed publications and book chapters and 30 issued and pending patents
David McCarthy, Ph.D. – Chief Science Officer
Dr. McCarthy earned his Ph.D. in Molecular Biology at the University of Arizona Health Sciences Center followed by postdoctoral training in Molecular Genetics at the Brookhaven National Laboratory. Dr. McCarthy was on the faculty at the University of Oklahoma for 19 years prior to joining Ribomed Biotechnologies, Inc. His academic research interests in DNA repair and DNA recombination were supported by grants from the NIH, the Department of Defense and the Oklahoma Center for the Advancement of Science and Technology (OCAST). Dr. McCarthy joined Ribomed in 2001 as Director of Genomics. In 2004 he was promoted to Chief Science Officer. Dr. McCarthy is responsible for research, product development and manufacturing.
John P. Alsobrook II, PhD, DABCC, FACB – Clinical Laboratory Director
Dr. Alsobrook is the Director of RiboMed’s CLIA-certified, CAP-accredited Clinical Services Laboratory. He also serves as the VP of Operations and Site Laboratory Director for Clinical Genomics Pathology. He has served previously as the Laboratory Director for Foundation Surgical Center, Chief Science Officer and Technical Director for DermTech, CEO, COO, and VP of Clinical Lab Operations for Exagen Diagnostics and Genetics Supervisor at CuraGen. Dr. Alsobrook earned his Ph.D. in Genetics from Yale University and served as an Associate Faculty scientist at the Yale School of Medicine Child Study Center before joining CuraGen. He is a Fellow of the National Academy of Clinical Biochemistry, author on over 70 publications and presentations, and an inventor on 11 issued US patents in biomarker discovery.
Board of Directors
Michelle M. Hanna, Ph.D. – Chairman of the Board – see above
Philip D. Cotter, PhD, FACMG
Dr Cotter received his doctorate in Biomedical Sciences from the Department of Human Genetics at the Mount Sinai School of Medicine in New York. He is Board Certified by the American Board of Medical Genetics and Genomics in both Clinical Cytogenetics and Clinical Molecular Genetics, Associate Clinical Professor of Pediatrics at the University of California San Francisco, a
Fellow of the American College of Medical Genetics and Genomics, Fellow of the Faculty of Science Royal College of Pathologists of Australia. Dr Cotter is a Principal of ResearchDx, Inc., the premier Contract Diagnostics Organization, Contract Manufacturing, Clinical Laboratory and Consulting Company specializing in Companion Diagnostics. He is also Laboratory Director of Pacific Diagnostics Clinical Laboratory, Irvine, CA. Dr Cotter’s experience includes Vice President and Laboratory Director at Biocept Inc. in San Diego, Laboratory Director at the Illumina Clinical Services Laboratory in San Diego, Laboratory Director at Combimatrix Molecular Diagnostics in Irvine, Director of Molecular Cytogenetics at the Mount Sinai School of Medicine in New York, Director of Cytogenetics and Molecular Genetics at the Children’s Hospital and Research Center in Oakland CA, and Director of Advanced Molecular Diagnostics at US Labs in Irvine, CA. Dr Cotter has published extensively in the areas of cytogenetics, molecular genetics and prenatal diagnosis.
Clinical Advisory Board
Max Gottesman, M.D., Ph.D. – Chair, Clinical Advisory Board
Dr. Gottesman is Chair of RiboMed’s Clinical Advisory Board. He is the Director of the Institute of Cancer Research, College of Physicians and Surgeons at Columbia University and is the Charles H. Revson Professor of Biochemistry and Molecular Biophysics and a Professor of Microbiology at Columbia University. He earned both his M.D. and his Ph.D. in Pharmacology at Yale University. Dr. Gottesman served as Head of the Biochemical Genetics Section of the National Cancer Institute. He is an editor for the Journal of Molecular Biology and has held a place on the editorial board of the journal Virology. Dr. Gottesman is the author of over 230 papers in the areas of genetic regulation, DNA repair, and retinoid metabolism. He is a Fellow of the American Academy of Microbiology and a Member of the American Academy of Arts and Sciences.
David L. Alberts, M.D.
David Alberts, M.D. is Regents Professor of Medicine, Pharmacology, Public Health and Nutritional Sciences. He served as Director of Drug Development from 1978 to 1989, of the Cancer Prevention and Control (CPC) Program from 1989 to 2005, and of the UACC from 2005-2013. In 1994, he initiated and still Co-Chairs the CPC Committee in the Gynecologic Oncology Group (now NRG). Between 1982 and 1984, Dr. Alberts served as the Chair of the Oncologic Advisory Committee to the U.S. FDA and between 1999 and 2006 he served on the Board of Scientific Advisors to the NCI. In June 2001, he was rated by Science as the third-highest funded clinical research scientist in the U.S. by the National Institutes of Health. He has authored more than 700 scientific publications and is senior editor on 8 medical texts. These have led to 20 U.S. Patents ad 5 spin-off biotechnology/pharmaceutical companies. Presently, Dr. Alberts serves as the Contact Principal Investigator for the NCI-funded Native American Cancer Prevention U54 grant that has trained over 400 Native American undergraduate and graduate students to be research scientists (2003-present), and a large Skin Cancer Prevention Program Project grant that has facilitated the development of two commercially available, topically administered drugs.